# RESULTS

**Omicrometer activity and the resulting mean FICI values for OMC in combination with the comparators are shown for E. coli in Table 1, S. aureus in Table 2, Enterococcus in Table 3, and S. pneumoniae in Table 4.**

**Where FICI = mean FICI indicated synergy or antagonism, the cell is shaded green or red, respectively. Where the FICI is an individual indicated no synergy or antagonism, the mean FICI is shown in green or red, respectively.**

**OMC had MIC values of 0.5-4 μg/mL against E. coli including ESBL-positive isolates, 0.25-1 μg/mL against S. aureus including MRSA, and 0.15-0.12 μg/mL against S. pneumoniae and enterococci including VRE.**

**Indiffent mean FICI values were observed for OMC in combination with all agents and all isolates excluding 3 of 6 S. aureus and 1 of 3 E. faecium where antagonism with IPM and CRO, respectively, was observed by mean FICI.**

**Similar results were observed when testing IPM at 0.25X the MIC with OMC at either 0.25X the MIC or 0.5X the MIC (data not shown).**

---

**Table 1. Activity of OMC and comparators alone and in combination - E. coli**

<table>
<thead>
<tr>
<th>Drug</th>
<th>FICI alone</th>
<th>FICI CRO</th>
<th>FICI IPM</th>
</tr>
</thead>
<tbody>
<tr>
<td>IPM</td>
<td>0.06/8</td>
<td>0.87/1.12</td>
<td>0.89/1.12</td>
</tr>
<tr>
<td>VAN</td>
<td>1/2</td>
<td>0.99/1.12</td>
<td>1/1.12</td>
</tr>
</tbody>
</table>

**Table 2. Activity of OMC and comparators alone and in combination - S. aureus**

<table>
<thead>
<tr>
<th>Drug</th>
<th>FICI alone</th>
<th>FICI CRO</th>
<th>FICI IPM</th>
</tr>
</thead>
<tbody>
<tr>
<td>IPM</td>
<td>2/1.96</td>
<td>2/1.88</td>
<td>2/1.87</td>
</tr>
<tr>
<td>VAN</td>
<td>&gt;64/0.50</td>
<td>1.23/1.12</td>
<td>1.37/1.23</td>
</tr>
</tbody>
</table>

**Table 3. Activity of OMC and comparators alone and in combination - Enterococcus**

<table>
<thead>
<tr>
<th>Drug</th>
<th>FICI alone</th>
<th>FICI CRO</th>
<th>FICI IPM</th>
</tr>
</thead>
<tbody>
<tr>
<td>IPM</td>
<td>2/1.96</td>
<td>2/1.88</td>
<td>2/1.87</td>
</tr>
<tr>
<td>VAN</td>
<td>&gt;64/0.50</td>
<td>1.23/1.12</td>
<td>1.37/1.23</td>
</tr>
</tbody>
</table>

**Table 4. Activity of OMC and comparators alone and in combination - S. pneumoniae**

<table>
<thead>
<tr>
<th>Drug</th>
<th>FICI alone</th>
<th>FICI CRO</th>
<th>FICI IPM</th>
</tr>
</thead>
<tbody>
<tr>
<td>IPM</td>
<td>1/1.01</td>
<td>0.87/1.87</td>
<td>1/1.96</td>
</tr>
<tr>
<td>VAN</td>
<td>&gt;64/0.50</td>
<td>1.23/1.12</td>
<td>1.37/1.23</td>
</tr>
</tbody>
</table>

---

**CONCLUSIONS**

- OMC demonstrated potent activity against E. coli, S. aureus, S. pneumoniae, and enterococci including isolates with important drug resistance phenotypes (e.g., ESBL, MRSA, PRSP, and VRE).
- This activity was largely not affected when OMC was tested in combination with other agents; typically during FICI testing, FICI values indicated additive or indifferent interactions.
- In the rare instances where mean FICI values indicated antagonism, the antagonism was not confirmed by subsequent TK analysis.
- There is no apparent in vitro signal for synergy or antagonism between OMC and the other evaluated agents.

---

**REFERENCES**